Abstract
Objective: MSCs that have been isolated from different sources are expected to possess different secretion patterns which might influence the therapeutic mechanism in the disease environment. Introduction: Through their paracrine effects such as immunomodulation and trophic functions, mesenchymal stem cells (MSCs) have been reported to possess the therapeutic potential to be used as a viable treatment for various diseases. MSCs can be isolated from different sources including adipose tissue, bone marrow, placenta and Wharton's Jelly(WJ), and be expanded in vitro. Although they possess similar characteristics, the source of origin of the MSCs is thought to affect the overall secretion patterns and thus their applications in the disease environment. Methods: MSCs from different sources (adipose, bone marrow, placenta, WJ) were cultured in serum free MEM-α medium for 24 hours at 37°C 5% CO 2 . The collected media were mixed with protease inhibitors and were then concentrated up to 250-fold. The concentrated media was then mixed with lysis buffer consisting of 8M urea, 75mM NaCl, and 50mM Tris (pH 8.2). The protein mixtures were digested into peptide samples and were then scanned under LC-MS/MS. Secreted proteins that were identified were functionally analyzed by DAVID. Results: The features and patterns of secreted proteins were highly dependent on the source of the MSC. While a majority of the secreted proteins of MSCs from neonatal sources (placenta, WJ) was highly involved in the developmental process, secreted proteins of MSCs from adult sources (adipose, bone marrow) were related to biological regulation and metabolic process. Conclusion: This study shows that source difference is an aspect that needs to be considered for disease-specific mesenchymal stem cell therapeutics and personalized therapy of neurodegenerative diseases.
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Effect of single ketogenic diet containing medium chain triglycerides on cognitive functions in elderly adults Evidence suggests that elevation of plasma ketone body levels through oral intake of medium chain triglycerides (MCTs) may improve cognitive function. We aimed to examine the possible effects of single ketogenic diet on cognition in elderly nondemented subjects. Material and Method: Subjects were 20 non-demented adults over 60 years old (14 females, mean age; 66.3 ± 2.9 years) who underwent neurocognitive tests in 90 and 180 minutes after an oral intake of a diet (Meiji Ketonformula®) containing 20 g of MCTs and an isocaloric diet without MCTs on separate days. Results: Plasma levels of ketone bodies significantly increased in 60 through 180 minutes after the intake of MCTs compared to the placebo. Cognitive performance was also improved by the MCTs in working memory, executive function, and the composit cognitive score. The executive function improvement positively correlated with the increase of plasma β-hydroxybutyrate level. Discussion: Significant increase of plasma ketone concentration after 20g ingestion of MCTs may have a positive effect on cognitive functions, particularly working memory and executive function. The therapeutic potential of MCTs represents a promising new area of dementia research.
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Oylethanolamide Modulates Human Neural Responses to Food Stimuli in Obesity
Markus Leweke, Martin Grosshans, Falk Kiefer, Andreas MeyerLindenberg, Cathrin Rohleder, Carola Schaefer, Emanuel Schwarz, Heike Tost, Christian Vollmert, Sabine Vollstadt Central Institute of Mental Health, Germany Abstract Background: Obesity has emerged as a leading health threat and major risk factor for type 2 diabetes, cardiovascular disease, and hypertension. The neurobiological basis of overeating remains insufficiently known, hampering sufficient intervention strategies. Here we investigate oleoylethanolamide, an agonist of PPAR-α. It has been implicated in weight regulation in animals but its respective role in humans is still unclear. Methods: Associations between plasma oleoylethanolamide, BMI and associated neurobiological impact (fMRi response to food stimuli) in 21 obese patients (BMI≥30) and 24 controls were investigated. We hypothesized that oleoylethanolamide interacts with BMI and fMRI response to food stimuli and may be affected in obese patients. Results: Associations between oleoylethanolamide and BMI differed significantly depending on whether subjects were obese or not (P=0.02). For obese individuals, oleoylethanolamide showed a trend towards a positive correlation with BMI (P=0.06, rho=0.42) while this relationship was inverse for controls (P=0.07, rho=-0.34). We observed significant interactions between oleoylethanolamide and obesity on food-related brain activation in cortical areas associated with reward processing and interoceptive signaling (P=0.009). fMRI-investigation of food-craving suggests that identified brain areas may be involved in suppressing 'liking' of food, in non-obese subjects.
